CytomX Therapeutics is a biotechnology company focused on revolutionizing the monoclonal antibody field by creating a new generation of highly targeted antibody therapeutics. CytomX's novel Probody™ Platform offers a highly differentiated approach to developing antibody therapeutics, and is based on a robust and growing intellectual property estate.
Market
Monoclonal Antibody Therapeutics
Coinvestors
Canaan Partners, Pfizer Strategic Investments Group, Third Rock Ventures